Csaba Vilmányi, Zsolt L Nagy, György S Reusz, László Ablonczy
{"title":"初步诊断对儿童心脏移植预后的影响。","authors":"Csaba Vilmányi, Zsolt L Nagy, György S Reusz, László Ablonczy","doi":"10.3390/jcdd12060205","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Pediatric heart transplantation (HTX) remains the only therapeutic option for end-stage heart failure not amenable to conventional surgical or catheter interventions. We reviewed our pediatric HTX outcomes according to primary diagnosis.</p><p><strong>Patients and methods: </strong>Sixty-two patients underwent HTX between 01/2007 and 12/2022. Patients were divided into congenital heart disease (CHD, n = 20) and cardiomyopathy (CMP, n = 42) groups. All potential variables relevant to patient recovery and long-term survival with endpoints of retransplantation or death were analyzed.</p><p><strong>Results: </strong>CHD patients underwent HTX after significantly more multiple major cardiac surgeries per patient (2.5 [0-5]) than CMP patients (0.5 [0-2], <i>p</i> < 0.01), without notable allosensitization. Post-HTX recovery was longer in CHD (mean mechanical ventilation 7 vs. 3 days, <i>p</i> = 0.001), likely due to longer surgical time (468 vs. 375 min, <i>p</i> = 0.037). There were no significant differences in the frequency of rejections between the two groups (4/20 vs. 9/42). Midterm survival was slightly better (85/70% <i>p</i> = NS) in CMP (median follow-up 44.5 [0-177] months).</p><p><strong>Conclusion: </strong>Our study confirmed good short- and long-term outcomes of pediatric HTX in both CMP and CHD. The longer postoperative recovery in CHD did not lead to higher mortality. No higher pretransplant hypersensitization was observed, possibly explaining the lack of difference in the number and severity of rejections.</p>","PeriodicalId":15197,"journal":{"name":"Journal of Cardiovascular Development and Disease","volume":"12 6","pages":""},"PeriodicalIF":2.4000,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12194210/pdf/","citationCount":"0","resultStr":"{\"title\":\"Impact of Primary Diagnosis on the Outcome of Heart Transplantation in Children.\",\"authors\":\"Csaba Vilmányi, Zsolt L Nagy, György S Reusz, László Ablonczy\",\"doi\":\"10.3390/jcdd12060205\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Pediatric heart transplantation (HTX) remains the only therapeutic option for end-stage heart failure not amenable to conventional surgical or catheter interventions. We reviewed our pediatric HTX outcomes according to primary diagnosis.</p><p><strong>Patients and methods: </strong>Sixty-two patients underwent HTX between 01/2007 and 12/2022. Patients were divided into congenital heart disease (CHD, n = 20) and cardiomyopathy (CMP, n = 42) groups. All potential variables relevant to patient recovery and long-term survival with endpoints of retransplantation or death were analyzed.</p><p><strong>Results: </strong>CHD patients underwent HTX after significantly more multiple major cardiac surgeries per patient (2.5 [0-5]) than CMP patients (0.5 [0-2], <i>p</i> < 0.01), without notable allosensitization. Post-HTX recovery was longer in CHD (mean mechanical ventilation 7 vs. 3 days, <i>p</i> = 0.001), likely due to longer surgical time (468 vs. 375 min, <i>p</i> = 0.037). There were no significant differences in the frequency of rejections between the two groups (4/20 vs. 9/42). Midterm survival was slightly better (85/70% <i>p</i> = NS) in CMP (median follow-up 44.5 [0-177] months).</p><p><strong>Conclusion: </strong>Our study confirmed good short- and long-term outcomes of pediatric HTX in both CMP and CHD. The longer postoperative recovery in CHD did not lead to higher mortality. No higher pretransplant hypersensitization was observed, possibly explaining the lack of difference in the number and severity of rejections.</p>\",\"PeriodicalId\":15197,\"journal\":{\"name\":\"Journal of Cardiovascular Development and Disease\",\"volume\":\"12 6\",\"pages\":\"\"},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2025-05-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12194210/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Cardiovascular Development and Disease\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3390/jcdd12060205\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cardiovascular Development and Disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/jcdd12060205","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
摘要
儿童心脏移植(HTX)仍然是终末期心力衰竭的唯一治疗选择,不能接受传统的手术或导管干预。我们根据初步诊断回顾了我们的儿童HTX结果。患者和方法:62例患者于2007年1月至2022年12月接受HTX治疗。将患者分为先天性心脏病组(CHD, n = 20)和心肌病组(CMP, n = 42)。所有与患者恢复和长期生存相关的潜在变量均以再移植或死亡为终点进行分析。结果:冠心病患者(2.5例[0-5])比CMP患者(0.5例[0-2],p < 0.01)在多次心脏大手术后接受HTX治疗,且无明显的同种异体致敏作用。冠心病htx术后恢复时间较长(平均机械通气7天对3天,p = 0.001),可能是由于手术时间较长(468分钟对375分钟,p = 0.037)。两组之间的排斥频率无显著差异(4/20 vs 9/42)。CMP的中期生存期略好(85/70% p = NS)(中位随访44.5[0-177]个月)。结论:我们的研究证实了儿童HTX治疗CMP和CHD的短期和长期效果良好。冠心病患者术后恢复时间较长并不导致死亡率增高。没有观察到更高的移植前超敏反应,可能解释了在数量和严重程度上缺乏差异的排斥反应。
Impact of Primary Diagnosis on the Outcome of Heart Transplantation in Children.
Introduction: Pediatric heart transplantation (HTX) remains the only therapeutic option for end-stage heart failure not amenable to conventional surgical or catheter interventions. We reviewed our pediatric HTX outcomes according to primary diagnosis.
Patients and methods: Sixty-two patients underwent HTX between 01/2007 and 12/2022. Patients were divided into congenital heart disease (CHD, n = 20) and cardiomyopathy (CMP, n = 42) groups. All potential variables relevant to patient recovery and long-term survival with endpoints of retransplantation or death were analyzed.
Results: CHD patients underwent HTX after significantly more multiple major cardiac surgeries per patient (2.5 [0-5]) than CMP patients (0.5 [0-2], p < 0.01), without notable allosensitization. Post-HTX recovery was longer in CHD (mean mechanical ventilation 7 vs. 3 days, p = 0.001), likely due to longer surgical time (468 vs. 375 min, p = 0.037). There were no significant differences in the frequency of rejections between the two groups (4/20 vs. 9/42). Midterm survival was slightly better (85/70% p = NS) in CMP (median follow-up 44.5 [0-177] months).
Conclusion: Our study confirmed good short- and long-term outcomes of pediatric HTX in both CMP and CHD. The longer postoperative recovery in CHD did not lead to higher mortality. No higher pretransplant hypersensitization was observed, possibly explaining the lack of difference in the number and severity of rejections.